Protective Effect of Fish Oil Supplementation on Exercise-Induced Bronchoconstriction in Asthma (original) (raw)
Related papers
2014
Asthma is the most frequent chronic disease among young adults, not least in the western societies, with an even higher frequency among elite athletes. Asthma consists of airway inflammation and smooth muscle contraction, normally treated with antiasthma therapy, some of which have side effects. n-3 LCPUFA in fish oil (FO) has antiinflammatory effects, and some studies have shown clinical effects of FO on asthma. We aimed to study if FO has an anti-asthma effect in elite athletes with asthma. The study was a randomized, double-blinded clinical trial. Ten elite athletes with a medical certificate allowing the use of asthma medication, age 15-46 years, were recruited among elite athletes supported by the Team Denmark Organization. All subjects had a positive mannitol test prior to enrollment. Depending on whether they used inhaled corticosteroids or not, the subjects were randomly assigned in pairs to either FO (2 g EPA and 1.3 g DHA) or soy oil capsules (SO) for 8 weeks. Change in forced expiratory volume (FEV 1) after exercise, NO excretion, sputum cell count and use of medication were measured before and after intervention. There was a slight trend towards increased exercise-induced decrease in lung function, use of asthma medication and respiratory inflammation in the FO-group, but the changes were neither significant nor clinically relevant.
Cogent Medicine, 2016
Asthma is a common and prevalent health problem, globally affecting over 300 million individuals. Observational and intervention studies have shown beneficial effects of omega-3 [Eicosapentaenoic Acid (EPA) and Docosahexaenoic acid (DHA)] on asthma and exercise-induced bronchoconstriction (EIB). Due to health side effects with pharmacological medication, use of complementary therapies including omega-3 supplementation is gaining impetus. A double-blinded randomised crossover pilot study with 3 weeks of supplementation (3.2 g EPA and 2.2 g DHA or placebo) was conducted to assess the effect of omega-3 supplementation in physically active males with EIB (n = 9, 21 ± 0.9 years, Forced Expiratory Volume in 1-s/Forced Vital Capacity (FEV 1 /FVC) = 77 ± 1.4). At the start of study, participants showed abnormal lung function, typical drop of >10% in their FEV 1 following exercise-challenge tests; elevated levels of Exhaled-breath Nitric oxide, FeNO (>40 ppb). The 3-week supplementation resulted in a significant improvement in post-exercise pulmonary function (PF) (<10% drop in post-exercise FEV 1 /FVC), supported by significant reduction in serum IL-6 levels (37% reduction). Although no significant changes were observed for Peripheral Blood Mononuclear Cell (PBMC) total lipid composition for EPA/DHA, non-significant increase in total PBMC EPA/DHA
Lipids in Health and Disease
Background Many patients suffering from exercise-induced asthma (EIA) have normal lung function at rest and show symptoms and a decline in FEV1 when they do sports or during exercise-challenge. It has been described that long-chain polyunsaturated fatty acids (LCPUFA) could exert a protective effect on EIA. Methods In this study the protective effect of supplementation with a special combination of n-3 and n-6 LCPUFA (sc-LCPUFA) (total 1.19 g/ day) were investigated in an EIA cold air provocation model. Primary outcome measure: Decrease in FEV1 after exercise challenge and secondary outcome measure: anti-inflammatory effects monitored by exhaled NO (eNO) before and after sc-LCPUFA supplementation versus placebo. Results Ninety-nine patients with exercise-induced symptoms aged 10 to 45 were screened by a standardized exercise challenge in a cold air chamber at 4 °C. Seventy-three patients fulfilled the inclusion criteria of a FEV1 decrease > 15% and were treated double-blind place...
Global Medical & Health Communication (GMHC), 2020
Fish oil contains omega-3 as an anti-inflammatory effect that can inhibit the production of arachidonic acid 5-lipoxygenase (ALOX5), an enzyme that aggravates the inflammation of the lungs that cause asthma. This study aims to determine the effect of omega-3 from fish oil on improving lung function with peak expiratory flow (PEF) value in patients with outpatient asthma in Surabaya. The research design used in this research is pre-post test design and lung function examination by using a peak flow meter. Then follow up every week for four weeks during the use of fish oil, and the results of his research were analyzed by t test. The study was conducted from April 2017 until January 2018 in Surabaya. The sample of the study was 27 adult asthma patients. The results showed that most of the study subjects had an increase in PEF value every week. Besides, there was a significant increase of PEF values gradually at T0 (before intervention) to T4 (intervention for four weeks), indicating a...
Effects of Fish oil and Dexamethasone in Experimentally-Induced Bronchial Asthma
Australian journal of basic and applied sciences, 2012
Background: Asthma is characterized by airway hyper-responsiveness, inflammation, obstruction and pathological remodelling. Objectives: To evaluate the efficacy of fish oil (FO) alone or combined with half the dose of dexamethasone (DEX) in experimentally-induced bronchial asthma. Material and Methods: Rats were allocated into 7 groups. Group 1 exposed to saline aerosol (normal control). Asthma was induced in the remaining groups by ovalbumin (OVA) sensitization (1 mg/kg OVA; i.p.) for 3 consecutive days followed by 1% OVA challenge (1 day/week for 3 weeks). One group was left untreated (positive control). In the remaining groups, test agents were orally administered 1 h before each OVA challenge as follows: group 3 received dexamethasone (DEX; 1 mg/kg), groups 4-6: received FO (1, 2 and 3 g/kg) and group 7 received FO (1.5 g/kg) plus DEX (0.5 mg/kg). Lung function tests were assessed 12 min after the last OVA challenge and 24 h thereafter, blood films were prepared for assessment o...
Free Radical Biology and Medicine, 2009
Epidemiological and clinical evidence has suggested that increased dietary intake of fish oil containing w-3 fatty acids including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may be associated with a reduced risk of asthma. However, interventional studies on these effects have been equivocal and controversial. Free radical oxidation products of lipids and cyclooxygenases-derived prostaglandins are believed to play an important role in asthma, and fish oil supplementation may modulate the levels of these critical lipid mediators. We employed a murine model of allergic inflammation produced by sensitization to ovalbumin (OVA) to study the effects of fish oil supplementation on airway inflammation. Our studies demonstrated that ω-3 fatty acids were dose-dependently incorporated into mouse lung tissue after dietary supplementation. We examined the oxidative stress status by measuring the levels of isoprostanes (IsoPs), the gold standard for oxidative stress in vivo. OVA challenge caused significant increase of F 2 -IsoPs in mouse lung, suggesting an elevated level of oxidative stress. Comparing to the control group, fish oil supplementation led to a significant reduction of F 2 -IsoP (from arachidonic acid) with a concomitant increase of F 3 -IsoPs (from EPA) and F 4 -IsoPs (from DHA). Surprisingly, however, fish oil supplementation enhanced production of pro-inflammatory cytokine IL-5 and IL-13. Furthermore, fish oil supplementation suppressed the production of pulmonary protective PGE 2 in the bronchoalveolar lavage (BAL) while level of urinary metabolite of the PGE 2 was increased. Our data suggest that augmented lung inflammation after fish oil supplementation may be due to the reduction of PGE 2 production in the lung and these dichotomous results bring into question the role of fish oil supplementation in the treatment of asthma.
Lipids, 2013
Episodes of acute exacerbation are the major clinical feature of asthma and therefore represent an important focus for developing novel therapies for this disease. There are many reports that the n-3 fatty acids found in fish oil exert anti-inflammatory effects, but there are few studies of the action of fish oil on airway smooth muscle (ASM) function. In the present investigation, we evaluated the effect of fish oil supplementation on smooth muscle force of contraction in ovalbumin-induced asth-
PLOS ONE, 2016
The prevalence of asthma has increased in recent decades, which may be related to higher dietary intake of (n-6) polyunsaturated fatty acids (PUFA) and lower intake of (n-3) PUFA, e.g., those contained in fish oil. The objective of this study was to determine if dietary PUFA enrichment decreases mucus production or the inflammatory response associated with ovalbumin (OVA)-induced allergic lung inflammation. Mice (n = 10/group) were fed control, 20% fish oil, or 20% corn oil enriched diets for a total of 12 weeks. At 8 and 10 weeks, mice were given an intraperitoneal injection of saline (10 control-fed mice) or OVA (30 remaining mice). Once at 10 weeks and on 3 consecutive days during week 12, mice were challenged by nebulizing with saline or OVA. Mice were euthanized 24 hours after the last challenge and blood was collected for plasma FA analysis. Bronchoalveolar lavage (BAL) fluid was collected to determine cell composition and Th2-type cytokine (IL-4, IL-13) concentrations. Periodic acid-Schiff (PAS) + mucus-producing cells and CD45+ inflammatory cell infiltrates in lung tissue were quantified using morphometric analysis. Relative abundance of mRNA for mucin (Muc4, Muc5ac, and Muc5b) and Th2-type cytokine (IL-4, IL-5, and IL-13) genes were compared with ß-actin by qPCR. Supplementation with either corn oil or fish oil effectively altered plasma FA profiles towards more (n-6) FA or (n-3) FA, respectively (P < 0.0001). Sensitization and challenge with OVA increased the proportion of neutrophils, lymphocytes, and eosinophils, and decreased the proportion of macrophages and concentrations of IL-13 in BAL fluid; increased the percentage of PAS+ mucus-producing cells and PLOS ONE |